Volume | 142 |
|
|||||
News | - | ||||||
Day High | 0.248 | Low High |
|||||
Day Low | 0.248 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
EOM Pharmaceutical Holdings Inc (PK) | IMUC | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.248 | 0.248 | 0.248 | 0.248 | 0.199 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
3 | 142 | US$ 0.248 | US$ 35 | - | 0.0182 - 0.40 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
14:48:58 | 1 | US$ 0.191 | USD |
EOM Pharmaceutical Holdings Inc (PK) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
US$ 28.09M | 113.27M | - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
EOM Pharmaceutical (PK) News
Date | Time | Source | News Article |
---|---|---|---|
8/02/2023 | 14:11 | Edgar (US Regulatory) | Form RW - Registration Withdrawal Request |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IMUC Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.14 | 0.248 | 0.14 | 0.2065427 | 1,060 | 0.108 | 77.14% |
1 Month | 0.16499 | 0.248 | 0.14 | 0.1784479 | 1,627 | 0.08301 | 50.31% |
3 Months | 0.212 | 0.30 | 0.11 | 0.1987528 | 4,271 | 0.036 | 16.98% |
6 Months | 0.1852 | 0.3999 | 0.0182 | 0.2254345 | 3,113 | 0.0628 | 33.91% |
1 Year | 0.25 | 0.40 | 0.0182 | 0.2502728 | 3,908 | -0.002 | -0.80% |
3 Years | 0.55 | 0.94 | 0.0182 | 0.4432352 | 6,440 | -0.302 | -54.91% |
5 Years | 0.0249 | 0.98 | 0.012 | 0.1097931 | 33,948 | 0.2231 | 895.98% |
EOM Pharmaceutical (PK) Description
The Company is a clinical-stage pharmaceutical company focused on the development of novel therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Our development pipeline consists of multiple programs and clinical indications at various stages of development. Our portfolio currently consists of two product candidates: EOM613 and EOM147. |